Free tool
FAERS Monitor: Betadine
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 018634 or its brand name (Betadine, Povidone-Iodine). Reports on generic versions are filed under their own applications.
Reports
3,733
Serious
3,018
81% of reports
Hospitalization
1,150
Death reported
423
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use472
- endophthalmitis384
- drug hypersensitivity375
- drug ineffective306
- rash277
- toxic anterior segment syndrome235
- nausea228
- pain213
- eye pain182
- product use in unapproved indication176
- vision blurred158
- hypersensitivity154
- dyspnoea153
- confusional state151
- rheumatoid arthritis143
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 17 |
| 2005 | 11 |
| 2006 | 38 |
| 2007 | 13 |
| 2008 | 25 |
| 2009 | 36 |
| 2010 | 77 |
| 2011 | 29 |
| 2012 | 129 |
| 2013 | 142 |
| 2014 | 203 |
| 2015 | 141 |
| 2016 | 230 |
| 2017 | 335 |
| 2018 | 315 |
| 2019 | 359 |
| 2020 | 203 |
| 2021 | 176 |
| 2022 | 259 |
| 2023 | 178 |
| 2024 | 250 |
| 2025 | 317 |
| 2026 | 250 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,426 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| toxic anterior segment syndromeSignal | 235 | 1548.1 | 1344.9 | 283,873 |
| endophthalmitisSignal | 384 | 385.2 | 349.2 | 137,431 |
| eye painSignal | 182 | 18.2 | 15.8 | 2,945 |
| drug hypersensitivitySignal | 375 | 10.9 | 9.9 | 3,401 |
| rheumatoid arthritisSignal | 143 | 7.1 | 6.0 | 747 |
| vision blurredSignal | 158 | 6.5 | 5.6 | 732 |
| confusional stateSignal | 151 | 5.3 | 4.5 | 522 |
| hypersensitivitySignal | 154 | 4.7 | 4.0 | 445 |
| product use in unapproved indicationSignal | 176 | 4.0 | 3.5 | 398 |
| rashSignal | 277 | 3.6 | 3.2 | 524 |
| off label useSignal | 472 | 3.0 | 2.8 | 671 |
| pain | 213 | 2.0 | 1.7 | 101 |
| nausea | 228 | 1.6 | 1.4 | 56 |
| dyspnoea | 153 | 1.5 | 1.3 | 28 |
| drug ineffective | 306 | 1.3 | 1.2 | 23 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.